Heart failure is a recognized complication of human immunodeficiency virus (HIV) infection dating back to the first case report in 1986.1 Over the subsequent years, the prevailing view of heart failure (HF) in HIV infection has evolved significantly. It is commonly suggested and at least 1 review has shown that in the era of antiretroviral therapy (ART), systolic dysfunction has become less common than diastolic dysfunction in people living with HIV (PLWH).2 Heart failure with reduced ejection fraction (HFrEF) and HIV-associated cardiomyopathies are thought to be pertinent mostly to PLWH in the era before widespread access to ART or in developing countries.3 In this issue of JAMA Cardiology, robust data from a large epidemiological study provide key insights into the contemporary epidemiology of HF in PLWH.4
Bloomfield GS, Felker GM. Heart Failure With Reduced Ejection Fraction in Human Immunodeficiency Virus Infection: The More Things Stay the Same. JAMA Cardiol. 2017;2(5):476–477. doi:10.1001/jamacardio.2017.0282
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: